Our Story

The future of Advanced Therapies

The Advanced Therapies Congress has hosted Europe’s largest commercially focused ATMP event in the UK for the past 18 years, and now we’re bringing our show to Philadelphia, Pennsylvania’s cell and gene hub!

What makes us different?

The Advanced Therapies Congress focuses on tackling challenges at each stage of development to accelerate development of next generation therapies to benefit patients.  We bring together decision makers from key biotech and pharma companies, putting forward a good ratio of buyers and sellers in our audience. 

Start-ups: our start-up village hosts early-stage companies for our audience to do business with early stage and mid stage biotech companies: a cross section of the developmental pipeline, buyers from every stage of development are present.

Networking: our networking app, Terrapinn Events App, facilitates networking for all attendees, creating a world-class environment for sponsors, speakers and guests alike. 

With 8 tracks of content, the agenda covers everything from manufacturing, supply chain & logistics, pricing &market access, to developments in key therapeutic areas; cell therapy, gene therapy, gene modified cell therapy, gene editing, stem cells, regenerative medicine, and much more.

WHY PHILADELPHIA?

Recognized as the birthplace of cell and gene therapy, Philadelphia is ideally situated in the heart of the Northeast easily accessible from major east coast biotech hubs such as Boston and Raleigh, with direct transport links further afield to both domestic and international destinations. With the number of cell and gene therapy companies in the Greater Philadelphia area doubling since 2019, $4.2 billion has been invested in CGT projects in Philadelphia over the last 5 years, as the sector continues to grow. 

Greater Philadelphia is home to over 1,200 life science companies with over 70,000 employees. Including over 60 cell and gene R&D companies and 10,000 workers with expertise in cell and gene therapy. Philadelphia has a thriving ecosystem of world-renowned academic institutions, leading biopharma companies, healthcare facilities and supporting clinical research firms. This extensive, collaborative network fosters the development of groundbreaking technologies. From large pharmaceutical companies to university spinouts, Pennsylvania’s gene and cell therapy cluster is broad and diverse. The scientific prowess and talented workforce underpin leading cell and gene therapy and biopharmaceutical companies based in the area including:

AstraZeneca - Bristol Myers Squibb - GlaxoSmithKline (GSK) -  Adaptimmune Therapeutics - Spark Therapeutics - Fate Therapeutics - Tmunity Therapeutics - Taysha Gene Therapies - Cabaletta Bio - Carisma Therapeutics - Passage Bio - Excision BioTherapeutics - Century Therapeutics